HER kinase inhibition in patients with HER2- and HER3-mutant cancers. (Q50115014)

http://europepmc.org/abstract/MED/29420467

25 February 2018

title

HER kinase inhibition in patients with HER2- and HER3-mutant cancers. (English)

1 reference

http://europepmc.org/abstract/MED/29420467

25 February 2018

corrigendum / erratum

Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers

0 references

author

Sarina Piha-Paul

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Víctor Moreno

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Emiliano Calvo

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Sherene Loi

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

David M Hyman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Helen Won

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Jordi Rodon

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Cristina Saura

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Geoffrey I Shapiro

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Dejan Juric

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

David I Quinn

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Bernard Doger

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Ingrid A Mayer

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Valentina Boni

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Albert C Lockhart

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Joseph P Erinjeri

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Maurizio Scaltriti

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Gary A Ulaner

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Juber Patel

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Jiabin Tang

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Hannah Beer

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

S Duygu Selcuklu

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Aphrothiti J Hanrahan

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Nancy Bouvier

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Myra Melcer

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Rajmohan Murali

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Alison M Schram

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Lillian M Smyth

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Komal Jhaveri

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Bob T Li

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Alexander Drilon

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

James J Harding

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Gopa Iyer

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Barry S Taylor

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Michael F Berger

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Richard E Cutler

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Feng Xu

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Anna Butturini

38

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Lisa D Eli

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Grace Mann

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Cynthia Farrell

41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Alshad S Lalani

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Richard P Bryce

43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Carlos L Arteaga

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

José Baselga

46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

David B Solit

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Funda Meric-Bernstam

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

language of work or name

English

0 references

publication date

31 January 2018

1 reference

http://europepmc.org/abstract/MED/29420467

25 February 2018

published in

Nature

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

554

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

7691

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

189-194

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nature25475

2 June 2020

exact match

0 references

cites work

Accelerating Discovery of Functional Mutant Alleles in Cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

AKT Inhibition in Solid Tumors With AKT1 Mutations

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Precision oncology: Charting a path forward to broader deployment of genomic profiling

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Implementing Genome-Driven Oncology

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Exploring genomic alteration in pediatric cancer using ProteinPaint

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

HER2 missense mutations have distinct effects on oncogenic signaling and migration.

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

HER2 activating mutations are targets for colorectal cancer treatment

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Clonal status of actionable driver events and the timing of mutational processes in cancer evolution

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

MSIsensor: microsatellite instability detection using paired tumor-normal sequence data

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Signatures of mutational processes in human cancer

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Oncogenic ERBB3 mutations in human cancers

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Activating HER2 mutations in HER2 gene amplification negative breast cancer

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Absolute quantification of somatic DNA alterations in human cancer

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

KEGG: kyoto encyclopedia of genes and genomes

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

26 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

26 August 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

2 November 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5808581

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

30 November 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNATURE25475

inferred from DOI database lookup

7 January 2021

based on heuristic

OncoKB: A Precision Oncology Knowledge Base

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNATURE25475

inferred from DOI database lookup

7 January 2021

based on heuristic

Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNATURE25475

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NATURE25475

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

2 June 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29420467%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

1 reference